Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi AppTec
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
- Contract Research Organization-CRO
- Laboratory Testing Services
- Medical Devices
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Crelux GmbH
- Faxian Therapeutics
- JW Biotechnology (Shanghai) Co., Ltd
- ResearchPoint Global
- STA Pharmaceutical Co., Ltd.
- WuXi PharmaTech
- WuXi Merger Limited
- XenoBiotic Laboratories, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.